An Audit to Evaluate the Etiologies and Preventability of Hyperkalemia in Inpatients: Focus on Modifiable Risk Factors and Medication-Related Triggers
DOI:
https://doi.org/10.70749/ijbr.v3i4.1089Keywords:
Hyperkalemia, Inpatient Safety, Modifiable Risk Factors, Medication-Induced Hyperkalemia, Clinical AuditAbstract
Background: Hyperkalemia, defined as a serum potassium level >5.0 mmol/L, is a frequent yet underrecognized clinical emergency in hospitalized patients. It is associated with substantial morbidity and mortality, particularly among individuals with chronic kidney disease (CKD), diabetes mellitus, and cardiovascular diseases. Medication-related factors such as use of renin-angiotensin-aldosterone system inhibitors and NSAIDs contribute significantly to its occurrence. Objective: This audit aimed to evaluate the etiologies and preventability of hyperkalemia in inpatients, with a focus on modifiable clinical risk factors and drug-related triggers. Methods: A retrospective audit was conducted at Lady Reading Hospital, Peshawar, over a six-month period. Adult inpatients with serum potassium levels >5.5 mmol/L were included, excluding those on dialysis or with familial potassium disorders. Data on demographics, comorbidities, medications, laboratory findings, and outcomes were extracted and analyzed. Preventability was assessed using Institute for Safe Medication Practices (ISMP) criteria. Results: Among 152 patients (mean age: 61.4 ± 13.2 years), 60.5% were male. CKD (49.3%), hypertension (62.5%), and diabetes (38.2%) were common comorbidities. Medication-related triggers were identified in 69.1% of cases, particularly ACE inhibitors (34.9%) and potassium-sparing diuretics (26.3%). A total of 45.4% of hyperkalemic episodes were deemed preventable, with inadequate monitoring (68.1%) and inappropriate drug use in renal impairment (49.3%) as leading causes. Mortality occurred in 5.9% of patients. Conclusion: Nearly half of hyperkalemia episodes in this tertiary care setting were preventable. Enhanced surveillance, appropriate drug adjustments, and regular electrolyte monitoring can significantly mitigate this risk and improve patient outcomes.
Downloads
References
Raffee, L. A., Alawneh, K. Z., Ababneh, M. J., Hijazi, H. H., Al abdi, R. M., Aboozour, M. M., Alghzawi, F. A., & Al-Mistarehi, A. (2022). Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: A prospective study. International Journal of Emergency Medicine, 15(1). https://doi.org/10.1186/s12245-022-00422-8
Bulloch, M. N., Cardinale-King, M., Cogle, S., Radparvar, S., Effendi, M., Jagpal, S., & Dixit, D. (2024). Correction of electrolyte abnormalities in critically ill patients. Intensive Care Research, 4(1), 19-37. https://doi.org/10.1007/s44231-023-00054-3
Zitzmann, M. (2024). Testosterone deficiency and chronic kidney disease. Journal of Clinical & Translational Endocrinology, 37, 100365. https://doi.org/10.1016/j.jcte.2024.100365
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023). Hyperkalemia in chronic kidney disease: A focus on potassium lowering pharmacotherapy. Expert Opinion on Pharmacotherapy, 24(16), 1775-1789. https://doi.org/10.1080/14656566.2023.2245756
Sarnowski, A., Gama, R. M., Dawson, A., Mason, H., & Banerjee, D. (2022). Hyperkalemia in chronic kidney disease: Links, risks and management. International Journal of Nephrology and Renovascular Disease, 15, 215-228. https://doi.org/10.2147/ijnrd.s326464
Larivée, N. L., Michaud, J. B., More, K. M., Wilson, J., & Tennankore, K. K. (2022). Hyperkalemia: Prevalence, predictors and emerging treatments. Cardiology and Therapy, 12(1), 35-63. https://doi.org/10.1007/s40119-022-00289-z
Amin, A., Moon, R., Agiro, A., Rosenthal, N., Brown, H., Legg, R., & Pottorf, W. (2022). In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia. The American Journal of the Medical Sciences, 364(4), 444-453. https://doi.org/10.1016/j.amjms.2022.04.029
Sun, J., Liu, Q., Seery, S., Sun, L., Yuan, Y., Wang, W., Wang, Y., Cui, Z., Wang, Y., Wang, Y., Zhu, J., Zhang, M., Lai, Y., & Jin, K. (2024). The impact of hyperkalemia on ICU admission and mortality: A retrospective study of Chinese emergency department data. BMC Emergency Medicine, 24(1). https://doi.org/10.1186/s12873-024-01011-z
Rafique, Z., Fortuny, M. J., Kuo, D., Szarpak, L., Llauger, L., Espinosa, B., Gil, V., Jacob, J., Alquézar-Arbé, A., Andueza, J. A., Garrido, J. M., Aguirre, A., Fuentes, M., Alonso, H., Lucas-Imbernón, F. J., Bibiano, C., Burillo-Putze, G., Núñez, J., Mullens, W., … Miró, Ò. (2023). Hyperkalemia in acute heart failure: Short term outcomes from the EAHFE registry. The American Journal of Emergency Medicine, 70, 1-9. https://doi.org/10.1016/j.ajem.2023.05.005
Cheng, S., Shen, H., Han, Y., Han, S., & Lu, Y. (2024). Association between stress hyperglycemia ratio index and all-cause mortality in critically ill patients with atrial fibrillation: A retrospective study using the MIMIC-IV database. Cardiovascular Diabetology, 23(1). https://doi.org/10.1186/s12933-024-02462-1
Baracaldo-Santamaría, D., Cala-Garcia, J. D., Medina-Rincón, G. J., Rojas-Rodriguez, L. C., & Calderon-Ospina, C. (2022). Therapeutic drug monitoring of Antifungal agents in critically ill patients: Is there a need for dose optimisation? Antibiotics, 11(5), 645. https://doi.org/10.3390/antibiotics11050645
Yu, Y., Vangaveti, V. N., Schnetler, R. J., Crowley, B. J., & Mallett, A. J. (2024). Hyperkalaemia among hospital admissions: Prevalence, risk factors, treatment and impact on length of stay. BMC Nephrology, 25(1). https://doi.org/10.1186/s12882-024-03863-w
Shibata, S., & Uchida, S. (2021). Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management. Therapeutic Apheresis and Dialysis, 26(1), 3-14. https://doi.org/10.1111/1744-9987.13721
Fishbane, S., Charytan, D. M., Chertow, G. M., Ford, M., Kovesdy, C. P., Pergola, P. E., Pollock, C., & Spinowitz, B. (2022). Consensus-based recommendations for the management of Hyperkalemia in the hemodialysis setting. Journal of Renal Nutrition, 32(4), e1-e14. https://doi.org/10.1053/j.jrn.2021.06.003
Massicotte-Azarniouch, D., Canney, M., Sood, M. M., & Hundemer, G. L. (2023). Managing Hyperkalemia in the modern era: A case-based approach. Kidney International Reports, 8(7), 1290-1300. https://doi.org/10.1016/j.ekir.2023.04.016
Van Boemmel-Wegmann, S., Bauer, C., Schuchhardt, J., Hartenstein, A., James, G., Pessina, E., Beeman, S., Edfors, R., & Pecoits-Filho, R. (2024). Hyperkalemia incidence in patients with non-dialysis chronic kidney disease: A large retrospective cohort study from United States clinical care. Kidney Medicine, 6(10), 100879. https://doi.org/10.1016/j.xkme.2024.100879
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023). Hyperkalemia in chronic kidney disease: A focus on potassium lowering pharmacotherapy. Expert Opinion on Pharmacotherapy, 24(16), 1775-1789. https://doi.org/10.1080/14656566.2023.2245756
Rastogi, A., Collins, A., Kelepouris, E., Kotzker, W., Middleton, J. P., Rajpal, M., Roy-Chaudhury, P., & Chertow, G. M. (2024). Practical considerations and implementation of sodium-glucose Co-transporter-2 inhibitors in chronic kidney disease: Who, when, and how? A position statement by nephrologists. Journal of Primary Care & Community Health, 15. https://doi.org/10.1177/21501319241259905
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
